CPT1 Antibody

What are the different CPT1 isoforms and how do they differ functionally?

CPT1 exists in three main isoforms, each with distinct tissue distribution and functions:

• CPT1A: Predominantly expressed in liver, kidney, and other tissues. Functions as a rate-limiting enzyme in fatty acid oxidation. Observed molecular weight is approximately 88 kDa .

• CPT1B: Primarily expressed in heart and skeletal muscle tissue. Calculated molecular weight is 64 kDa, though observed weight in experiments is 75-85 kDa .

• CPT1C: Specifically expressed in the endoplasmic reticulum of neurons. Unlike other isoforms, CPT1C functions primarily as a palmitoyl thioesterase and has very low or no carnitine palmitoyltransferase catalytic activity. It modulates glutamate receptor trafficking through depalmitoylation of GRIA1 and binds malonyl-CoA to regulate ceramide levels, affecting spine maturation and systemic energy homeostasis .

The tissue-specific distribution of these isoforms necessitates careful selection of antibodies depending on the research focus.

What types of CPT1 antibodies are available for research use?

Several types of CPT1 antibodies are available, varying in host species, clonality, and target specificity:

Each antibody has been validated for specific applications and species reactivity, making selection crucial for experimental success.

What are the optimal dilutions and conditions for using CPT1 antibodies in different applications?

Optimal working dilutions vary by application and specific antibody:

For CPT1A (E3Y1V) Rabbit mAb (#97361):

• Western Blotting: 1:1000

• Immunoprecipitation: 1:50

• Immunohistochemistry (Paraffin): 1:100 - 1:400

• Immunofluorescence: 1:400 - 1:1600

• Flow Cytometry (Fixed/Permeabilized): 1:200 - 1:800

For CPT1B-specific antibody (22170-1-AP):

• Western Blot: 1:2000 - 1:10000

• Immunoprecipitation: 0.5-4.0 μg for 1.0-3.0 mg of total protein lysate

• Immunohistochemistry: 1:50 - 1:500

• Immunofluorescence: 1:50 - 1:500

For optimal results with IHC applications using CPT1B antibody, antigen retrieval with TE buffer pH 9.0 is recommended, though citrate buffer pH 6.0 can be used as an alternative .

How should I validate the specificity of CPT1 antibodies in my experimental system?

Validating antibody specificity is crucial for reliable results. Consider these approaches:

• Positive and negative tissue controls: Use tissues known to express or lack the specific CPT1 isoform. For example, CPT1B antibody validation should include heart and skeletal muscle tissue (positive controls) .

• Knockdown/knockout validation: Use samples from CPT1 knockout models as negative controls. Several knockout models have been developed, including Albumin-Cre; Cpt1a floxed mice, Albumin-Cre; Cpt1b floxed mice, and Albumin-Cre; Cpt2 floxed mice .

• Western blot verification: Confirm the antibody detects a band of the expected molecular weight. Note that observed weights may differ from calculated weights due to post-translational modifications (e.g., CPT1B has a calculated weight of 64 kDa but is observed at 75-85 kDa) .

• Cross-reactivity assessment: If studying a specific isoform, verify the antibody does not cross-react with other CPT1 isoforms using recombinant proteins or tissues with differential expression.

• Multiple antibody concordance: Use antibodies from different sources targeting different epitopes and compare results for consistency.

How can I measure CPT1 enzyme activity rather than just protein levels?

Measuring CPT1 enzyme activity provides functional information beyond protein expression levels. Several methodologies exist:

• Traditional radioisotope method: Historically, CPT1 activity has been measured using tritium-labeled L-[³H]carnitine. While highly sensitive, this approach has limitations regarding operational safety, scalability, and equipment access due to the hazards of managing tritium waste .

• Spectrophotometric assays: These measure the released CoA-SH from palmitoyl-CoA using 5,5′-dithiobis-(2-nitrobenzoic acid) (DTNB). The reaction produces 2-thio-5-nitrobenzoic acid (TNB), which can be measured at 412 nm. This method does not require purified CPT1 enzyme and can be performed with mitochondrial extracts .

• Fluorogenic assays: Similar to spectrophotometric approaches but utilizing fluorescent detection for greater sensitivity .

• Direct expression system: Recent developments include expressing CPT1a in Expi293 cells and isolating mitochondrial extracts as a scalable source of catalytically active CPT1a. This approach enables high-throughput screening of CPT1 inhibitors without the need for purified enzyme .

When measuring activity, consider that CPT1 is a membrane-bound protein requiring the mitochondrial membrane environment for proper structure and function, making recombinant sources often catalytically inactive .

What are the technical challenges in studying CPT1C compared to CPT1A and CPT1B?

CPT1C presents unique research challenges compared to other isoforms:

• Limited enzymatic activity: Unlike CPT1A and CPT1B, CPT1C has very low or no carnitine palmitoyltransferase catalytic activity, making traditional activity assays less applicable .

• Subcellular localization: CPT1C is specifically expressed in the endoplasmic reticulum of neurons, not in mitochondria, requiring different isolation protocols and experimental approaches .

• Functional diversity: CPT1C functions as a palmitoyl thioesterase and modulates processes like AMPAR trafficking through depalmitoylation of GRIA1. It also binds malonyl-CoA and couples it to ceramide levels. This functional diversity necessitates multiple assay types beyond traditional CPT1 activity measurements .

• Tissue specificity: The neuron-specific expression pattern requires specialized neuronal cell models or brain tissue samples, increasing experimental complexity compared to more widely expressed isoforms .

• Protein interactions: CPT1C regulates AMPR trafficking through interaction with SACM1L phosphatidylinositol-3-phosphatase in a malonyl-CoA dependent manner, requiring specialized interaction studies to fully characterize its function .

Why might I observe multiple bands or unexpected molecular weights when using CPT1 antibodies in Western blot?

Multiple bands or unexpected molecular weights in Western blots with CPT1 antibodies may occur for several reasons:

• Post-translational modifications: CPT1 proteins undergo various modifications that alter their molecular weight. For example, CPT1B has a calculated weight of 64 kDa but is typically observed at 75-85 kDa in experimental settings .

• Isoform detection: Some antibodies may detect multiple CPT1 isoforms if they target conserved regions. Verify the specificity of your antibody for the particular isoform of interest.

• Protein degradation: CPT1 proteins, especially when extracted from membrane environments, may undergo degradation, resulting in lower molecular weight bands.

• Alternative splicing: CPT1 genes can undergo alternative splicing, producing protein variants of different sizes.

• Sample preparation issues: Incomplete denaturation or reduction can cause anomalous migration patterns. Ensure complete denaturation with appropriate buffers and heating.

• Cross-reactivity: Antibodies may cross-react with structurally similar proteins, particularly other acyltransferases.

To address these issues, consider using positive controls with known expression patterns, verifying with knockout/knockdown samples, or using antibodies targeting different epitopes of the same protein.

What are the best tissue preservation and antigen retrieval methods for CPT1 immunohistochemistry?

Optimal tissue preservation and antigen retrieval for CPT1 immunohistochemistry varies by isoform:

For CPT1B antibody (22170-1-AP):

• The recommended antigen retrieval method is TE buffer at pH 9.0

• Alternatively, citrate buffer at pH 6.0 can be used, though possibly with reduced sensitivity

• Validated positive tissues include mouse heart tissue

General recommendations for all CPT1 isoforms:

• Fixation: 10% neutral buffered formalin for 24-48 hours is typically suitable. Avoid overfixation which can mask epitopes.

• Tissue processing: Standard paraffin embedding procedures are compatible with most CPT1 antibodies.

• Section thickness: 4-5 μm sections are optimal for good morphology and antibody penetration.

• Antigen retrieval optimization: If recommended methods yield poor results, consider testing both heat-induced epitope retrieval (HIER) and enzymatic retrieval methods:

  • HIER: Try citrate (pH 6.0), EDTA (pH 8.0-9.0), or Tris-EDTA (pH 9.0) buffers

  • Enzymatic: Proteinase K or trypsin can sometimes expose epitopes resistant to HIER

• Blocking: Use species-appropriate blocking sera to reduce background staining, particularly important with polyclonal antibodies.

• Controls: Include positive control tissues (e.g., heart/skeletal muscle for CPT1B, liver for CPT1A) and negative controls (antibody diluent only) with each staining run.

How do CPT1 knockout models differ from studies using CPT1 inhibitors?

CPT1 knockout models and inhibitor studies offer complementary but distinct approaches to understanding CPT1 function:

Knockout Models:

• Complete elimination: Genetic knockout models completely eliminate the target protein, providing insights into essential functions.

• Isoform specificity: Models can target specific isoforms (CPT1A, CPT1B, or CPT1C) allowing for differentiation of isoform-specific functions.

• Developmental effects: Constitutive knockouts may reveal developmental roles that might be missed in adult inhibitor studies.

• Compensatory mechanisms: Long-term adaptation may occur, with other metabolic pathways compensating for the loss of CPT1 function.

• Tissue specificity: Conditional knockouts (e.g., Albumin-Cre; Cpt1a floxed mice) allow for tissue-specific elimination of CPT1 .

Inhibitor Studies:

• Temporal control: Inhibitors can be applied at specific time points, allowing for acute vs. chronic studies.

• Dose-dependent effects: Inhibitor concentration can be titrated to achieve partial inhibition, unlike the binary nature of genetic knockouts.

• Reversibility: Effects can be reversed upon inhibitor withdrawal.

• Off-target effects: Most inhibitors have some degree of non-specific activity.

• Incomplete inhibition: Even at maximal doses, complete inhibition may not be achieved.

Research has shown that Cpt1-knockout cells completely lack the ability for cell-autonomous oxidation of fatty acids, while inhibitor studies may show partial effects depending on inhibitor specificity and dosage .

What are the best experimental approaches for studying the differential roles of CPT1 isoforms in specific tissues?

To study differential roles of CPT1 isoforms in specific tissues, consider these approaches:

• Tissue-specific conditional knockout models: Models like Albumin-Cre; Cpt1a floxed (liver-specific), Albumin-Cre; Cpt1b floxed, and combination models (Albumin-Cre; Cpt1a floxed; Cpt1b floxed) enable precise examination of isoform contributions in specific tissues .

• Isoform-specific antibodies: Use highly specific antibodies for each isoform to quantify expression levels across tissues:

  • CPT1A (E3Y1V) Rabbit mAb for liver studies

  • CPT1B-specific antibody for heart and skeletal muscle research

  • Anti-Cpt1c/CPT1-B antibody for neuronal studies

• Comparative activity assays: Develop tissue-specific mitochondrial extracts to measure and compare native CPT1 activity across tissues using spectrophotometric or fluorogenic assays .

• RNA-seq analysis: Compare transcriptomic profiles between wildtype and knockout models. Several datasets are publicly available through GEO (e.g., GSE267915, GSE267916) .

• Metabolomic profiling: Compare metabolite profiles in different tissues to identify isoform-specific effects on fatty acid metabolism and related pathways.

• High-throughput inhibitor screening: Using platforms like the modified colorimetric CoA detection method, screen for isoform-selective inhibitors to probe specific functions .

• Co-immunoprecipitation studies: Identify tissue-specific protein interaction partners for different CPT1 isoforms to understand context-dependent functions.

How are CPT1 antibodies being used to study the relationship between fatty acid metabolism and neurological disorders?

CPT1 antibodies, particularly those targeting CPT1C, are increasingly valuable in studying the intersection of metabolism and neurological function:

• Synaptic plasticity: Research using Anti-Cpt1c/CPT1-B antibodies has revealed that CPT1C is necessary for proper spine maturation in neurons, suggesting a direct link between fatty acid metabolism and synaptic development .

• AMPAR trafficking: Immunofluorescence and immunoprecipitation studies have demonstrated that CPT1C modulates glutamate receptor (AMPAR) trafficking to the plasma membrane through depalmitoylation of GRIA1, providing a mechanism connecting lipid metabolism to synaptic transmission .

• Malonyl-CoA sensing: CPT1C's ability to bind malonyl-CoA couples energy sensing to ceramide levels, potentially linking metabolic status to neuronal function and contributing to appetite control mechanisms .

• Neurodegenerative diseases: Emerging research is examining how alterations in CPT1 function correlate with neurodegenerative conditions, with antibody-based techniques providing critical tools for mapping expression changes in disease models.

• Metabolic regulation in the brain: Studies are investigating how CPT1 isoforms respond to metabolic challenges in the brain, with antibodies enabling determination of expression patterns during fasting, high-fat diet, or ketogenic states.

These applications highlight how CPT1 antibodies are essential for understanding the unique roles of CPT1 isoforms in neuronal metabolism and function, potentially leading to novel therapeutic approaches for neurological disorders with metabolic components.

What advances are being made in high-throughput screening methods for CPT1 inhibitors using antibody-based detection?

Recent advances in high-throughput screening for CPT1 inhibitors combine traditional enzymatic assays with novel antibody-based detection methods:

• Direct expression systems: Rather than purifying CPT1 (which often renders it inactive), researchers are now expressing CPT1a in Expi293 cells and isolating mitochondrial extracts as a scalable source of catalytically active enzyme for inhibitor screening .

• Modified colorimetric assays: Traditional DTNB-based assays measuring CoA release have been optimized for microplate formats, enabling screening of compound libraries against CPT1 activity .

• Antibody-based activity verification: After identifying potential inhibitors through activity assays, researchers use CPT1-specific antibodies to verify that observed activity changes correspond to actual CPT1 protein and not off-target effects.

• Cell-based phenotypic screens: High-content screening approaches using CPT1 antibodies for immunofluorescence detection can identify compounds that affect CPT1 localization or expression levels in cellular contexts.

• Validation cascades: Modern screening platforms employ a series of increasingly stringent assays, starting with high-throughput activity screens followed by antibody-based verification of target engagement.

A recent screening campaign using these approaches successfully identified chlorpromazine as a CPT1 inhibitor, demonstrating the validity of these modified high-throughput screening platforms .

What are the critical factors for successful immunoprecipitation of CPT1 proteins?

Successful immunoprecipitation (IP) of CPT1 proteins requires careful attention to several factors:

• Membrane protein considerations: As membrane-bound proteins, CPT1 isoforms require specialized lysis conditions to maintain solubility and native conformation. Consider using:

  • Non-denaturing detergents like NP-40, Triton X-100, or digitonin

  • Mild sonication to disrupt mitochondrial membranes

  • Avoidance of harsh ionic detergents that may disrupt antibody-epitope interaction

• Antibody selection and amounts:

  • For CPT1A: Use 1:50 dilution of CPT1A (E3Y1V) Rabbit mAb

  • For CPT1B: Use 0.5-4.0 μg antibody for 1.0-3.0 mg of total protein lysate

  • Monoclonal antibodies often provide higher specificity but may have lower affinity than polyclonals

• Validated tissue sources:

  • CPT1A: Liver tissue provides abundant source material

  • CPT1B: Mouse heart tissue and mouse skeletal muscle tissue have been validated for successful IP

  • CPT1C: Brain tissue or neuronal cultures are preferred

• Co-immunoprecipitation considerations: When studying protein interactions (like CPT1C with SACM1L), consider crosslinking to stabilize transient interactions or ensure lysis conditions preserve native protein complexes.

• Controls:

  • Include IgG-matched negative controls

  • Verify specificity with CPT1-knockout tissue/cell lysates when possible

  • Validate successful IP by immunoblotting a small portion of the IP product

How can I optimize immunofluorescence protocols for detecting CPT1 in specific subcellular compartments?

Optimizing immunofluorescence for subcellular localization of CPT1 isoforms requires consideration of their distinct localizations:

• Fixation optimization:

  • For mitochondrial CPT1A and CPT1B: 4% paraformaldehyde (10-15 minutes) preserves mitochondrial structures

  • For ER-localized CPT1C: Combined paraformaldehyde/glutaraldehyde fixation may better preserve ER morphology

  • Avoid methanol fixation which can disrupt membrane structures

• Permeabilization considerations:

  • Use mild detergents (0.1-0.2% Triton X-100, or 0.1% saponin)

  • For CPT1C in ER, digitonin (25-50 μg/ml) provides selective plasma membrane permeabilization while preserving ER structure

• Antibody dilutions and incubation:

  • For CPT1A: 1:400 - 1:1600 dilution is recommended

  • For CPT1B: 1:50 - 1:500 dilution is optimal

  • Extended incubation (overnight at 4°C) may improve signal-to-noise ratio

• Co-localization markers:

  • For CPT1A/B: Co-stain with mitochondrial markers (MitoTracker, Tom20, or COX IV)

  • For CPT1C: Use ER markers (calnexin, PDI, or Sec61β)

  • Include markers for relevant cell types in tissue sections

• Signal amplification:

  • For weak signals, consider tyramide signal amplification

  • Avoid excessive amplification which may obscure subcellular details

• Imaging considerations:

  • Use confocal microscopy for precise subcellular localization

  • Z-stacks with deconvolution can improve resolution of membrane structures

  • Super-resolution techniques may be necessary to distinguish outer vs. inner mitochondrial membrane localization

• Validated positive controls:

  • For CPT1B: Mouse heart tissue has been validated for immunofluorescence